Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo and ArQule have entered into a license agreement to develop a new AKT inhibitor - ARQ 092.
Subscribe to our email newsletter
Both the companies have jointly developed ARQ 092 by utlizing ArQule Kinase Inhibitor Platform (AKIP) technology, as per the agreement signed in November 2008.
Daiichi Sankyo will retain all rights for the development , manufacturing and marketing of ARQ 092, as per the license agreement.
The companies said the ARQ 092 will be studied in cancer patients to identify its utility in targeting the AKT signaling pathway.
They also said that patient enrollment in the Phase 1 clinical trial with ARQ 092 is scheduled to open in the coming months.
Daiichi Sankyo R&D Unit head Kazunori Hirokawa said in addition to their own internal R&D capabilities, their strategic alliance partnerships, such as their collaborations with ArQule, allow them to combine forces to move more programs into clinical trials toward their common goal of improving and extending lives.